pulssipulsin

Pulssipulsin, also known as 7-de-oxy Psoralen, is a synthetic psoralen derivative used in the treatment of certain skin diseases. It is a heterocyclic compound that belongs to the class of furocoumarins.

Pulssipulsin is primarily used in the treatment of vitiligo, a chronic autoimmune disorder characterized by the loss of pigment-producing cells in the skin. The medication works by stimulating the production of melanin, the pigment responsible for skin color, through a process called photochemotherapy.

When pulssipulsin is administered orally and exposed to ultraviolet-A (UVA) radiation from sunlight or a specialized lamp, it combines with the skin's DNA, causing damage to abnormal cells. This damage leads to the repigmentation of affected skin areas, restoring their natural color.

Pulssipulsin has also been investigated for its potential therapeutic applications in other conditions, such as psoriasis, scleroderma, and skin cancers. However, its effectiveness in these areas is still being researched and may vary depending on the type and severity of the disease.

The use of pulssipulsin is associated with several side effects, including nausea, vomiting, diarrhea, and sensitivity to light. Patients are usually advised to avoid direct sun exposure and use protective clothing, sunscreen, and eye shields when undergoing treatment.

In 1993, pulssipulsin was withdrawn from the US market due to its potential for causing photosensitivity, a condition characterized by increased sensitivity to light, which can lead to pain, blistering, and scarring. However, it is still available in some countries for limited applications, and its use is strictly regulated to minimize the risk of adverse reactions.